



For Release

Hadasit Announces Hadassah Hospital's New Clinical Research Center

The Center is supported by a full service GMP facility for Phase I and Phase II studies

Jerusalem, Israel, May 30, 2007 --- Hadasit announced today the opening of the Hadassah Clinical Research Center (CRC) soon to be located at the new BioTechnology Park at Hadassah University Hospital in Ein Kerem, Israel. The CRC, together with the Hadasit team, provides all of the services and facilities needed for pre-clinical through Phase III drug and medical device studies.

“Hadassah is a world class research institution that has a rich history of clinical excellence. Our team is comprised, not just of talented physicians, but of experienced research professionals who respect study protocols and work in accordance with the highest international standards. This is a crucial deliverable especially for Phase I safety studies,” said Professor Yoseph Caraco, Director of the Clinical Research Center and a globally recognized clinical pharmacologist.

As a referral Center, Hadassah regularly treats comparably large scale populations of patients with a potpourri of conditions and illnesses. This reality enables trial recruitment for most studies to proceed reasonably smoothly.

“Our IRB has extremely rigorous standards. However, though the bar is set high, study sponsors will no longer have to sift through months of bureaucracy. We now have a point person to answer sponsor questions and to process the required paperwork for the IRB which will soon meet more frequently than the existing once a month,” said Professor Caraco.

The Center is supported by a full service GMP Center located on the premises of Hadasah Medical Center. The GMP team, supervised by Dr. Linda Rasooly, can accommodate the protocol requests of any Phase I or Phase II study. In addition, the team is willing to draft GMP protocols for a requesting study sponsor, whose personnel it will also train to participate in the lab process.

-MORE-

“Conducting a trial at the Clinical Research Center affords the study sponsor the convenience of a *package deal*. The company has access to a special, fully equipped pre-clinical unit on the premises. It also receives a top rate clinical team, a large patient pool, and a GMP facility that not only provides the highest quality of production but is also less expensive than other GMP sites around the world. In fact, just recently, we manufactured a drug for MGVS that has been FDA approved for a trial in the U.S.,” said Dr. Rasooly.

About Hadasit

Hadasit (www.hadasit.co.il) was established as a subsidiary of Hadassah Medical Organization (HMO) in Jerusalem, Israel to promote and commercialize its continuously generated intellectual property (IP), purposed to helping solve the problems of modern medicine. Hadasit guides technologies from innovation to commercial application. For additional information or to schedule an interview, please contact Marjie Hadad, Media Liaison, Hadasit, at +972-54-536-5220 or e-mail pr@marjihadad.com or marjie@netvision.net.il.